V-Bio Ventures

Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Aphea.Bio focuses on developing innovative agricultural products aimed at enhancing crop health and yields. The company specializes in creating next-generation biopesticides derived from natural microorganisms, which serve as sustainable alternatives to traditional chemical pesticides facing regulatory challenges. Additionally, Aphea.Bio produces biostimulants that promote crop growth by enhancing nutrient uptake from the soil. Utilizing proprietary technologies, the company is dedicated to discovering new biocontrol and biostimulant products that help farmers sustainably manage fungal diseases, pests, and weeds, ultimately improving crop productivity and environmental health.

Animab is a biotechnology company focused on enhancing livestock health through innovative monoclonal antibody technology. By leveraging advanced research in animal science, Animab develops products that aim to improve animal welfare, reduce operational costs, and promote sustainability in livestock farming. Their proprietary antibodies are designed to mimic secretory IgA, a natural antibody found in colostrum and milk, which provides critical protection for piglets during the vulnerable post-weaning phase. These antibodies target specific intestinal pathogens while preserving the healthy microbiome, ensuring that piglets remain healthy and resilient during this crucial developmental period. Through its solutions, Animab seeks to benefit animals, producers, and consumers alike.

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

ExeVir Bio BV, founded in 2020 and based in Zwijnaarde, Belgium, specializes in developing single-domain antibody-based therapies aimed at combating viral infections. The company leverages a llama-derived antibody technology platform to create robust antiviral treatments that offer broad protection against coronaviruses. Notably, it is developing VHH72-FC, an antibody that targets a highly conserved region on the spikes of SARS-CoV-2, crucial for the virus's entry into human cells. ExeVir Bio's rapid response platform for antivirals allows for an agile approach to emerging health threats, enabling the swift generation of drug candidates. The therapeutics produced through this innovative technology are designed to be stable, cost-effective, and accessible on a global scale.

Orionis Biosciences is a biotechnology company focused on early-stage drug discovery and development, particularly targeting oncology and immunotherapies. Headquartered in Waltham, Massachusetts, with additional research facilities in Ghent, Belgium, the company utilizes a range of innovative technologies to create conditionally active drug modalities aimed at treating diseases with significant unmet medical needs. By inducing molecular proximity and cooperativity, Orionis enhances drug potency and precision, allowing for novel target access. Their approach facilitates the development of a diverse pipeline of drug candidates, including therapies that engage both adaptive and innate immune systems. The company collaborates with strategic partners, including VIB in Belgium, and is supported by a team of seasoned entrepreneurs and scientists, as well as a transatlantic network of investors.

Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

Aphea.Bio focuses on developing innovative agricultural products aimed at enhancing crop health and yields. The company specializes in creating next-generation biopesticides derived from natural microorganisms, which serve as sustainable alternatives to traditional chemical pesticides facing regulatory challenges. Additionally, Aphea.Bio produces biostimulants that promote crop growth by enhancing nutrient uptake from the soil. Utilizing proprietary technologies, the company is dedicated to discovering new biocontrol and biostimulant products that help farmers sustainably manage fungal diseases, pests, and weeds, ultimately improving crop productivity and environmental health.

OCTIMET oncology’s overall strategy is to advance the development of discovery stage molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy.

Orionis Biosciences is a biotechnology company focused on early-stage drug discovery and development, particularly targeting oncology and immunotherapies. Headquartered in Waltham, Massachusetts, with additional research facilities in Ghent, Belgium, the company utilizes a range of innovative technologies to create conditionally active drug modalities aimed at treating diseases with significant unmet medical needs. By inducing molecular proximity and cooperativity, Orionis enhances drug potency and precision, allowing for novel target access. Their approach facilitates the development of a diverse pipeline of drug candidates, including therapies that engage both adaptive and innate immune systems. The company collaborates with strategic partners, including VIB in Belgium, and is supported by a team of seasoned entrepreneurs and scientists, as well as a transatlantic network of investors.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.